Substitute for FORM 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of 1

Complete if Known					
Application Number:	10/612,298				
Filing Date:	July 2, 2003				
First Named Inventor:	Byron E. Anderson				
Group Art Unit:	1639				
Confirmation Number:	5133				
Examiner Name:	Gross, Christopher M.				
Attorney Docket Number:	45240-105719				

U.S. PATENT DOCUMENTS						
		U.S. Patent Docu	ment			
Examiner Initials	Doc. No	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
		F	oreign Patent Documer	it			Tran	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	3.3	wo	94/26296		Houghten Pharmaceuticals, Inc.	Nov. 24, 1994		
	34	wo	01/39796	A2	Neurochem Inc.	June 7, 2001		

D	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,		station
Examiner Doc. Incide name of the name of the magazine, journal	and/or country where published.	Yes	No**
3.5	Antifungal Activity," Bioorganic & Medicinal Chemistry Letters, 10 (16): 1779-1781 (2000).		
36	Copy of Supplementary Partial European Search Report issued in EP 03 76 3093 (2008).		
	35	Doc. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. Kundu et al., "Combinatorial Approach to Lead Optimization of a Novel Hexapeptide with Antifungal Activity," Bioorganic & Medicinal Chemistry Letters, 10 (16): 1779-1781 (2000).	Doc. No magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city yes and/or country where published. Kundu et al., "Combinatorial Approach to Lead Optimization of a Novel Hexapeptide with Antifungal Activity," Bioorganic & Medicinal Chemistry Letters, 10 (16): 1779-1781 (2000).

CHDS01 AOM 463552v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CG/

EXAMINER	/Christopher Gross/ (07/01/2008)	DATE CONSIDERED	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relavance professor 27 CEP 3 (46)(473)